Literature DB >> 6144502

Effects of antihypertensive drugs on endocrine function.

E P Brass.   

Abstract

Pharmacological treatment of hypertension can cause clinically significant alterations in endocrine function through effects on glucose homeostasis, thyroid and parathyroid hormones, adrenal steroid metabolism and reproductive/pituitary physiology. Long term use of thiazide diuretics causes deterioration in glucose tolerance, probably secondary to potassium depletion. Hypoglycaemic complications of beta-blockers (mainly the non-selective compounds) can be dramatic, especially in type I diabetics. Clonidine, diazoxide and calcium antagonists have all been associated with deterioration in glucose tolerance and their long term use should be avoided in type II diabetics if possible. Propranolol lowers T3 levels by decreasing the conversion of T4 to T3. Prazosin causes elevations in T4 and thyroid-stimulating hormone, while sodium nitroprusside use may result in hypothyroidism. Numerous agents are associated with sexual dysfunction, including methyldopa, reserpine, clonidine and spironolactone. Thiazide diuretics may cause hypercalcaemia, particularly in patients with hyperparathyroidism, by decreasing urinary calcium as well as directly influencing bone and gut calcium handling. Conversely, propranolol may decrease circulating parathyroid hormone levels and correct the hypercalcaemia seen in hyperparathyroidism. Awareness of drug-induced changes in endocrine function will facilitate the rational management of the hypertensive patient.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6144502     DOI: 10.2165/00003495-198427050-00004

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  120 in total

Review 1.  Drug therapy: clonidine, a new antihypertensive drug.

Authors:  W A Pettinger
Journal:  N Engl J Med       Date:  1975-12-04       Impact factor: 91.245

Review 2.  The abrupt discontinuation of antihypertensive treatment.

Authors:  S B Garbus; M A Weber; R T Priest; D D Brewer; F A Hubbell
Journal:  J Clin Pharmacol       Date:  1979 Aug-Sep       Impact factor: 3.126

3.  Hypoglycemia: a complication of treatment of hypertension with propranolol.

Authors:  R J Kallen; J H Mohler; H L Lin
Journal:  Clin Pediatr (Phila)       Date:  1980-08       Impact factor: 1.168

4.  beta-blockers or diuretics in hypertension? A six year follow-up of blood pressure and metabolic side effects.

Authors:  G Berglund; O Andersson
Journal:  Lancet       Date:  1981-04-04       Impact factor: 79.321

5.  Deterioration of glucose tolerance in hypertensive patients on prolonged diuretic treatment.

Authors:  P J Lewis; E M Kohner; A Petrie; C T Dollery
Journal:  Lancet       Date:  1976-03-13       Impact factor: 79.321

6.  changes in serum and urinary calcium during treatment with hydrochlorothiazide: studies on mechanisms.

Authors:  A S Brickman; S G Massry; J W Coburn
Journal:  J Clin Invest       Date:  1972-04       Impact factor: 14.808

7.  Effect of d- and dl-propranolol on glucose-stimulated insulin release.

Authors:  M G Myers; H F Hope-Gill
Journal:  Clin Pharmacol Ther       Date:  1979-03       Impact factor: 6.875

8.  Effect of prazosin on blood lipids and on thyroid function in hypertensive patients.

Authors:  M Velasco; H Silva; J Morillo; R Pellicer; A Urbina-Quintana; O Hernández-Pieretti
Journal:  J Cardiovasc Pharmacol       Date:  1982       Impact factor: 3.105

9.  Impairment of insulin secretion in man by nifedipine.

Authors:  D Giugliano; R Torella; F Cacciapuoti; S Gentile; M Verza; M Varricchio
Journal:  Eur J Clin Pharmacol       Date:  1980-11       Impact factor: 2.953

10.  Plasma corticosteroid concentrations during spironolactone administration: evidence for adrenal biosynthetic blockade in man.

Authors:  M L Tuck; J R Sowers; D B Fittingoff; J S Fisher; G J Berg; N D Asp; D M Mayes
Journal:  J Clin Endocrinol Metab       Date:  1981-06       Impact factor: 5.958

View more
  4 in total

1.  Finerenone Impedes Aldosterone-dependent Nuclear Import of the Mineralocorticoid Receptor and Prevents Genomic Recruitment of Steroid Receptor Coactivator-1.

Authors:  Larbi Amazit; Florian Le Billan; Peter Kolkhof; Khadija Lamribet; Say Viengchareun; Michel R Fay; Junaid A Khan; Alexander Hillisch; Marc Lombès; Marie-Edith Rafestin-Oblin; Jérôme Fagart
Journal:  J Biol Chem       Date:  2015-07-22       Impact factor: 5.157

2.  Inhibition by hydrochlorothiazide of insulin release and calcium influx in mouse pancreatic beta-cells.

Authors:  P E Sandström
Journal:  Br J Pharmacol       Date:  1993-12       Impact factor: 8.739

3.  Effects of captopril on diabetic nephropathy in hypertensive women.

Authors:  L Gonzalez-Sicilia de Llamas; A Garcia Alberola; M Lafuente Lopez-Herrera; T Fuente Jimenez; J Fernandez Pardo; J Hernandez Cascales
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

Review 4.  Non-insulin-dependent (type II) diabetes mellitus.

Authors:  W Rodger
Journal:  CMAJ       Date:  1991-12-15       Impact factor: 8.262

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.